To test whether pharmacologic inhibition was in fact specific to Mediator kinase function, we utilized dual CRISPR/Cas9 constructs47 to create knockout derivatives of both CDK8 and CDK19, CDK8 only, CDK19 only, or double-sham control knockouts in three KRAS-mutant cancer cell lines. The gene discussed is CDK19; the disease is cancer.